o-desmethyltramadol
Small moleculeexperimental
Desmetramadol, also known as O-desmethyltramadol (O-DSMT), is an opioid analgesic and the main active metabolite of tramadol. Tramadol is demethylated by the liver enzyme CYP2D6 to desmetramadol in the same way as codeine, and so similarly to the variation in effects seen with codeine, individuals who have a less active form of CYP2D6 will tend to have reduced analgesic effects from tramadol. Because desmetramadol itself does not need to be metabolized to induce an analgesic effect, it can be used in individuals with CYP2D6 inactivating mutations. — Wikipedia
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2018 (NCT03664921)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Mu opioid receptorAGONIST
OPRM agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDesmetramadol ↗
Also known as
- o-desmethyltramadol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03664921 | Phase 2 | Oct 1, 2018 | DF/Net Research, National Institute on Drug Abuse (NIDA), Syntrix Biosystems, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| DF/Net Research | For profit | 1 | 0 | 1 | 2018 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2018 |
| Syntrix Biosystems, Inc. | For profit | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1